IFIT1 polymorphisms predict interferon-α treatment efficiency for hepatitis B virus infection

Table 1 Patient charateristics

Patient characteristic	Total patient (n)
Total patient	225
Gender	225
Male	163 (72.4)
Female	62 (27.6)
Age	225
Median age (range)	26 (18-56)
Baseline ALT	225
Median (range)	150 (70-359)
Baseline AST	225
Median (range)	83 (30-294)
Baseline HBV DNA copies (log10IU/L)	225
Median (range)	7.36 (3.52-8.90)
HBV genotype	197
Type A	8 (4.1)
Type B	94 (47.7)
Type C	15 (7.6)
Type B + C	80 (40.6)
Virological response1	225
Response	83 (36.9)
Non-response	142 (63.1)
HBeAg seroconversion2	225
Response	61 (27.1)
Non-response	164 (72.9)
Combined response3	225
Response	35 (15.6)
Non-response	190 (84.4)
Sustained response4	225
Response	59 (26.2)
Non-response	166 (73.8)

¹Virological response was defined as serum HBV DNA level < 2000 IU/L at the end of the treatment;

²HBeAg seroconversion was defined as the loss of HBeAg and the presence of anti-HBe at the end of the treatment;

³Combined response was defined as the combination of HBeAg seroconversion and virological response, as well as the normalization of serum ALT at the end of the treatment;

⁴Sustained response was defined as the combined response at week 72 after the first dose of the treatment. ALT: Alanine aminotransferase; AST: Aspartate transaminase; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen.